Acumen Pharmaceuticals, Inc. (ABOS) annual balance sheet — 7-year assets, liabilities & equity history
| Total Current Assets | 133.09M | 122.25M | 178.31M | 246.62M | 180.33M | 198.66M | 44.43M | 7.18M |
| Cash & Short-Term Investments | 128.4M | 116.86M | 171.56M | 243.52M | 177.6M | 194.24M | 43.78M | 6.55M |
| Cash Only | 51.8M | 53.99M | 35.63M | 66.89M | 130.1M | 122.16M | 43.78M | 6.55M |
| Short-Term Investments | 76.6M | 62.88M | 135.93M | 176.64M | 47.5M | 72.08M | 0 | 0 |
| Accounts Receivable | 0 | 625K | 0 | 225K | 0 | 0 | 109K | 30K |
| Days Sales Outstanding | - | - | - | - | - | - | 27.71 | 6.45 |
| Inventory | 0 | 0 | 159K | 0 | 199K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 4.7M | 4.76M | 5.73M | 1.96M | 1.42M | 2.83M | 447K | 7K |
| Total Non-Current Assets | 535K | 581K | 60.69M | 63.51M | 16.26M | 31.67M | 0 | 144K |
| Property, Plant & Equipment | 0 | 0 | 339K | 503K | 270K | 36K | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 169K | 0 | 0 | 0 | 0 |
| Long-Term Investments | 32.47M | 0 | 59.97M | 62.55M | 15.84M | 31.62M | 0 | 0 |
| Other Non-Current Assets | 535K | 581K | 379K | 285K | 151K | 14K | 0 | 144K |
| Total Assets | 133.63M | 122.83M | 238.99M | 310.13M | 196.59M | 230.33M | 44.43M | 7.32M |
| Asset Turnover | 0.00x | - | - | - | - | - | 0.03x | 0.23x |
| Asset Growth % | -170.48% | -48.6% | -22.94% | 57.75% | -14.65% | 418.42% | 506.79% | - |
| Total Current Liabilities | 29.23M | 30.01M | 27.61M | 12.97M | 7.81M | 5.15M | 6.37M | 1.34M |
| Accounts Payable | 1.66M | 554K | 5.65M | 1.38M | 1.64M | 1.09M | 531K | 223K |
| Days Payables Outstanding | 9.91K | - | - | - | - | 32.27 | 24.24 | 9.49 |
| Short-Term Debt | 14.12M | 8.91M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 13.45M | 20.54M | 230K | 3.9M | 131K | 2.96M | 5.5M | 614K |
| Current Ratio | 4.55x | 4.07x | 6.46x | 19.01x | 23.08x | 38.60x | 6.98x | 5.35x |
| Quick Ratio | 4.55x | 4.07x | 6.45x | 19.01x | 23.06x | 38.60x | 6.98x | 5.35x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 16.92M | 22.4M | 29.57M | 30.18M | 0 | 0 | 56.65M | 17.4M |
| Long-Term Debt | 0 | 22.4M | 29.42M | 27.34M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 116K | 0 | 150K | 284K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 16.92M | 0 | 0 | 2.56M | 0 | 0 | 56.65M | 17.4M |
| Total Liabilities | 46.15M | 52.4M | 57.18M | 43.15M | 7.81M | 5.15M | 63.02M | 18.74M |
| Total Debt | 14.12M | 31.31M | 29.7M | 28.49M | 105K | 0 | 0 | 0 |
| Net Debt | -37.67M | -22.68M | -5.92M | -38.4M | -130M | -122.16M | -43.78M | -6.55M |
| Debt / Equity | 0.16x | 0.44x | 0.16x | 0.11x | 0.00x | - | - | - |
| Debt / EBITDA | -0.12x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.33x | - | - | - | - | - | - | - |
| Interest Coverage | -25.88x | -27.73x | -24.15x | -89.14x | - | - | - | - |
| Total Equity | 87.48M | 70.43M | 181.82M | 266.97M | 188.78M | 225.18M | -18.59M | -11.42M |
| Equity Growth % | -214.13% | -61.26% | -31.9% | 41.42% | -16.17% | 1311.25% | -62.79% | - |
| Book Value per Share | 1.38 | 1.16 | 3.03 | 5.49 | 4.65 | 5.88 | -0.65 | -0.40 |
| Total Shareholders' Equity | 87.48M | 70.43M | 181.82M | 266.97M | 188.78M | 225.18M | -18.59M | -11.42M |
| Common Stock | 7K | 6K | 6K | 6K | 4K | 4K | 0 | 0 |
| Retained Earnings | -467.2M | -446.46M | -325.13M | -222.8M | -170.43M | -127.57M | -26.96M | -19.64M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 21K | 83K | -48K | 312K | -751K | -231K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ABOS stock.
As of 2025, Acumen Pharmaceuticals, Inc. (ABOS) had total assets of $122.8M including $122.3M in current assets.
Acumen Pharmaceuticals, Inc. (ABOS) carries total debt of $31.3M, offset by $116.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Acumen Pharmaceuticals, Inc. (ABOS) has total shareholders' equity (book value) of $70.4M ($1.16 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Acumen Pharmaceuticals, Inc. (ABOS) reported a current ratio of 4.07x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.